about
A critical review of the analytical approaches for circulating tumor biomarker kinetics during treatmentExposure-effect population model of inolimomab, a monoclonal antibody administered in first-line treatment for acute graft-versus-host diseaseIdentification of the primary mechanism of action of an insulin secretagogue from meal test data in healthy volunteers based on an integrated glucose-insulin model.Chemotherapeutic errors in hospitalised cancer patients: attributable damage and extra costsSolid oral forms availability in children: a cost saving investigationUnderstanding polyspecificity within the substrate-binding cavity of the human multidrug resistance P-glycoproteinModel-based design of rituximab dosage optimization in follicular non-Hodgkin's lymphoma.Subcutaneous trastuzumab: development of a new formulation for treatment of HER2-positive early breast cancer.Early prediction of treatment resistance in low-risk gestational trophoblastic neoplasia using population kinetic modelling of hCG measurements.Prediction of tumour response induced by chemotherapy using modelling of CA-125 kinetics in recurrent ovarian cancer patients.Development of a drug-disease simulation model for rituximab in follicular non-Hodgkin's lymphoma.A mechanism-based approach for absorption modeling: the Gastro-Intestinal Transit Time (GITT) model.Can we predict chemo-induced hematotoxicity in elderly patients treated with pegylated liposomal doxorubicin? Results of a population-based model derived from the DOGMES phase II trial of the GINECO.Prognostic value of modeled PSA clearance on biochemical relapse free survival after radical prostatectomy.Dose adaptation of capecitabine based on individual prediction of limiting toxicity grade: evaluation by clinical trial simulation.A dynamic model of hand-and-foot syndrome in patients receiving capecitabine.Fractionation of daily dose increases the predicted risk of severe sorafenib-induced hand-foot syndrome (HFS).Advantages of prostate-specific antigen (PSA) clearance model over simple PSA half-life computation to describe PSA decrease after prostate adenomectomy.Dynamic modeling in ovarian cancer: an original approach linking early changes in modeled longitudinal CA-125 kinetics and survival to help decisions in early drug development.Predictors of prescription errors involving anticancer chemotherapy agentsLes enjeux de l’observance pour les nouvelles chimiothérapies par voie orale : intérêt du modèle pharmacocinétique-pharmacodynamique
P50
Q26862558-076FCB5A-C630-41E8-BA3C-566C0688EC97Q28299731-A812B53E-125F-494D-B12D-81493B3B1D80Q30578482-C38CF203-9E1E-46F2-BA0E-AAECE27AC32DQ34070132-98C6E03C-3A14-446B-8641-A87EBA531D40Q34570925-90DC4C12-FE63-46B5-BC46-3887DF52DE99Q35039337-1133C0BC-AAB4-4876-AE36-AE19F820E358Q36036378-A134A673-A671-4F33-B5F7-B00363BB5143Q36617983-E2FC1EA3-371E-4910-AAE2-71173E7CAD97Q36876448-18208F66-BAA2-4C21-A826-88C14E7D16CEQ37650730-57F58075-6E50-473C-B0E8-E891025519CBQ39937143-047C5ADB-AC5D-40D9-9C0C-277A1BEE278DQ41888193-4716553A-80C1-4B94-A263-AF09D8BEB3CCQ42445545-38D81DD9-3988-42CB-BD54-6F11CFF6A126Q43443818-49D8C77A-7477-44ED-AF66-F007F06B2914Q44002046-2924AECB-75BA-46D8-A3B6-2BAC6E94C446Q44014861-BBDD561D-7A19-4F8B-8A8A-57EBCAACDF63Q44252023-5CC9F139-BD26-4349-829F-EC52A9E7FCBCQ46623928-E3FD2242-C189-426F-A1FE-50355A44310BQ50670852-6AB85662-FBDB-4831-B6FE-704F6C5CCAF0Q63441538-ECE85809-39E1-4A8A-AB6E-88BDA676E6A6Q63441539-DBAC5A14-C68E-4DCD-A853-77B78AC75EA6
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Emilie Henin
@ast
Emilie Henin
@en
Emilie Henin
@es
Emilie Henin
@nl
Emilie Henin
@sl
type
label
Emilie Henin
@ast
Emilie Henin
@en
Emilie Henin
@es
Emilie Henin
@nl
Emilie Henin
@sl
prefLabel
Emilie Henin
@ast
Emilie Henin
@en
Emilie Henin
@es
Emilie Henin
@nl
Emilie Henin
@sl
P106
P21
P31
P496
0000-0001-7478-2154